Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bonnigheim – page 11

495 clinical trials in Bonnigheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bonnigheim at a glance
495
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

495 trials in Bonnigheim

Open in trial search

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitaet Des Saarlandes

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Alcohol abuse+1

Recruiting

Study on the Effects of Cannabidiol and Naltrexone on Alcohol Craving in Patients with Alcohol Dependence

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Zentralinstitut Fuer Seelische Gesundheit

Bladder cancer

Recruiting

Study of mRNA-4157 and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonrotoclax
  • Sponsor:BeOne Medicines AG

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bonnigheim

What the registry says about research in the country

01 Vaccine Development Research

Clinical trials focusing on meningococcal infection prevention through advanced vaccination strategies, specifically evaluating a new quadrivalent conjugate vaccine's long-term effectiveness.

  • Immunogenicity Assessment
  • Booster Dose Evaluation
  • Long-term Protection Studies

This multinational research aims to understand immune persistence and safety profiles in children and adolescents who received initial vaccination as toddlers.

02 Pediatric Immunology

Investigation of immune response patterns in different age groups, from children to adolescents, examining the effectiveness of vaccination schedules over extended periods.

  • Age-specific Response Analysis
  • Seroresponse Monitoring
  • Safety Profile Assessment

The research spans multiple European locations, including Finland, Germany, Spain, and Hungary, ensuring diverse population representation.

03 Preventive Medicine

Comprehensive evaluation of meningococcal disease prevention strategies, focusing on long-term protection through strategic booster dose timing.

  • 5-year Follow-up Studies
  • 10-year Protection Assessment
  • Multiple Serogroup Coverage

This research specifically targets protection against four key meningococcal serogroups: A, C, W, and Y.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.